Lughezzani Giovanni, Jeldres Claudio, Isbarn Hendrik, Perrotte Paul, Shariat Shahrokh F, Sun Maxine, Widmer Hugues, Arjane Philippe, Peloquin Francois, Pharand Daniel, Patard Jean-Jacques, Graefen Markus, Montorsi Francesco, Karakiewicz Pierre I
Cancer Prognosis and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
J Urol. 2009 Oct;182(4):1287-93. doi: 10.1016/j.juro.2009.06.018. Epub 2009 Aug 14.
A recent multi-institutional analysis of 995 patients treated for renal cell cancer questioned the relationship between tumor size and the synchronous metastasis rate. We revisited the hypothesis that metastatic potential is unrelated to tumor size.
We tested the relationship between tumor size and synchronous metastasis in 22,204 patients with T1a and T1b renal cell cancer diagnosed and/or treated with nephrectomy for clear cell, papillary or chromophobe histological subtypes in 1 of 9 Surveillance, Epidemiology and End Results registries between 1988 and 2004.
In the study population the synchronous metastasis rate was 9.6%, including 5.6% vs 14.2% for T1a vs T1b. Stratification by 1 cm tumor size intervals revealed that the rate increased with increasing tumor size, that is 4.8% at 1.0 cm or less, 4.2% at 1.1 to 2.0 cm, 4.9% at 2.1 to 3.0 cm, 7.1% at 3.1 to 4.0 cm, 12.1% at 4.1 to 5.0 cm, 13.3% at 5.1 to 6.0 cm and 18.4% 6.1 to 7.0 cm (chi-square trend p <0.001). Cubic spline analysis showed that tumor size was virtually linearly related to the synchronous metastasis rate. Stratification by histological subtype in patients treated with nephrectomy revealed that clear cell renal cell cancer was most frequently associated with synchronous metastasis. Finally, tumor size was an independent predictor of synchronous metastasis in multivariate regression models adjusted for age, gender, histological subtype and year of diagnosis quartiles.
Our study confirms that tumor size is an important determinant of the likelihood of synchronous metastasis in patients with T1a and T1b renal cell cancer. The synchronous metastasis rate directly increases with increasing tumor size. Even patients with small renal masses are at risk for synchronous metastasis and patients with clear cell renal cell cancer are at highest risk.
最近一项对995例接受肾细胞癌治疗患者的多机构分析对肿瘤大小与同步转移率之间的关系提出了质疑。我们重新审视了转移潜能与肿瘤大小无关这一假说。
我们在1988年至2004年期间,对9个监测、流行病学和最终结果登记处之一中诊断和/或接受肾切除术治疗的22204例T1a和T1b期肾细胞癌患者进行了肿瘤大小与同步转移之间关系的检测,这些患者的组织学亚型为透明细胞、乳头状或嫌色细胞。
在研究人群中,同步转移率为9.6%,其中T1a期为5.6%,T1b期为14.2%。按1厘米肿瘤大小间隔分层显示,转移率随肿瘤大小增加而升高,即1.0厘米及以下为4.8%,1.1至2.0厘米为4.2%,2.1至3.0厘米为4.9%,3.1至4.0厘米为7.1%,4.1至5.0厘米为12.1%,5.1至6.0厘米为13.3%,6.1至7.0厘米为18.4%(卡方趋势p<0.001)。三次样条分析显示,肿瘤大小与同步转移率几乎呈线性相关。对接受肾切除术患者按组织学亚型分层显示,透明细胞肾细胞癌最常与同步转移相关。最后,在根据年龄、性别、组织学亚型和诊断四分位数年份进行调整的多变量回归模型中,肿瘤大小是同步转移的独立预测因素。
我们的研究证实,肿瘤大小是T1a和T1b期肾细胞癌患者同步转移可能性的重要决定因素。同步转移率随肿瘤大小增加而直接升高。即使是小肾肿块患者也有同步转移风险,其中透明细胞肾细胞癌患者风险最高。